SCHEMBL5084412

SCHEMBL5084412

C=C(C(N)=O)C(N)CCCCC

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.46
GRIK2 Q13002 2/20 0.46
DPP7 Q9UHL4 2/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
GNAI3 P08754 1/20 0.44
GNAO1 P09471 1/20 0.44
GNAI1 P63096 1/20 0.44
LAP3 P28838 2/20 0.42
TP53 P04637 1/20 0.42
SLC15A1 P46059 1/20 0.42
OPRM1 P35372 1/20 0.41
DDAH1 O94760 1/20 0.40
GPR84 Q9NQS5 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
SPHK1 Q9NYA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883516 0.85 SLC1A2 (0.41) GRIK1GRIK2DPP7SLC1A2SLC1A1
SCHEMBL1886382 0.84 GRIK1 (0.50) GRIK1GRIK2DPP7SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL1883990 0.82 GRIK1 (0.49) GRIK1GRIK2DPP7SLC1A2SLC1A1
SCHEMBL28855294 0.80 CA2 (0.50) GRIK1GRIK2SLC1A2SLC1A1LAP3
SCHEMBL30539139 0.80 CA1 (0.53) TP53OPRM1GPR84CA1CA2
SCHEMBL1412205 0.80 CA2 (0.50) GRIK1GRIK2SLC1A2SLC1A1LAP3
SCHEMBL8085531 0.80 GPR84 (0.53) TP53GPR84CA1CA2SPHK1
SCHEMBL28522786 0.80 CA2 (0.50) GRIK1GRIK2SLC1A2SLC1A1LAP3
SCHEMBL8813489 0.79 GRIK1 (0.48) GRIK1GRIK2DPP7SLC1A2SLC1A1
SCHEMBL16326700 0.79 GRIK1 (0.52) GRIK1GRIK2DPP7SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028671-A1 Sequencing by Structure Assembly HARVARD COLLEGE (US) 2026-01-29 US disclosed
US-20250369043-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS INC (US) 2025-12-04 US disclosed
EP-4655423-A1 INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS Illumina, Inc. (US) 2025-12-03 EP disclosed
US-12467086-B2 Sequencing by structure assembly PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-11 US disclosed
EP-4612296-A1 COMPOSITIONS AND METHODS FOR PURIFYING POLYRIBONUCLEOTIDES Flagship Pioneering Innovations VI, LLC (US) 2025-09-10 EP disclosed
US-20250277224-A1 COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2025-09-04 US disclosed
US-12378600-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2025-08-05 US disclosed
US-12338474-B2 Compositions and methods for producing circular polyribonucleotides FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2025-06-24 US disclosed
US-20250188505-A1 PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) 2025-06-12 US disclosed
WO-2025097012-A1 METHODS OF SORTING SPERM BASED ON GENOTYPE MAVEN BONNIE E J (US) 2025-05-08 WO disclosed
CN-113841078-A Methods, devices and systems for analyte detection and analysis 阿尔缇玛基因组学公司 2021-12-24 CN disclosed
CN-113795887-A Method and system for sequence determination 阿尔缇玛基因组学公司 2021-12-14 CN disclosed
CN-111527044-A Method and system for sequence determination 阿尔缇玛基因组学公司 2020-08-11 CN disclosed
US-20180340020-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-11-29 US disclosed
US-10072065-B2 Peptide-mediated delivery of immunoglobulins across the blood-brain barrier MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2018-09-11 US disclosed
US-20170058017-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-03-02 US disclosed
US-8715923-B2 Protein scaffolds and viral particles for detecting analytes THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2014-05-06 US disclosed
US-20080220408-A1 Non-enveloped virus particles comprising a plurality of detectable fluorescent labels for use in solid support for detecting preferential particles in solutions THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SE (US) 2008-09-11 US disclosed
WO-2006124044-A2 PROTEIN SCAFFOLDS AND VIRAL PARTICLES FOR DETECTING ANALYTES GEORGE MASON UNIVERSITY (US) 2006-11-23 WO disclosed
EP-0155503-A1 Improvement in the dewatering of wet paper webs using mannich acrylamide polymers AMERICAN CYANAMID COMPANY (US) 1985-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028671-A1 Sequencing by Structure Assembly POLL, CPSF7, POLM GRIK1 4874/4885GRIK2 4870/4885DPP7 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.